From Wikipedia, the free encyclopedia
|(what is this?)|
Elotuzumab (also known as HuLuc63) is a humanized monoclonal antibody which is under phase III clinical investigation in relapsed multiple myeloma. In May 2014, it was granted "Breakthrough Therapy" designation by the FDA. 
- "PDL BioPharma, Development Pipeline - HuLuc63". Retrieved 2008-08-14.[dead link]
- "Bristol-Myers Squibb and AbbVie Receive U.S. FDA Breakthrough Therapy Designation for Elotuzumab, an Investigational Humanized Monoclonal Antibody for Multiple Myeloma" (Press release). Princeton, NJ & North Chicago, IL: Bristol-Myers Squibb. 2014-05-19. Retrieved 2015-02-05.
|This monoclonal antibody-related article is a stub. You can help Wikipedia by expanding it.|
|This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.|